Cargando…
Genetic screening for neovascular AMD: cost effective…not so quick
The following is a response to Brown and colleagues (Int J Retin Vitr 1:19, 2015), who analyzed the cost effectiveness of genetic screening for neovascular AMD in Category 3 (intermediate). As explained in this letter, it is premature to propose that genetic screening is cost effective in this setti...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088460/ https://www.ncbi.nlm.nih.gov/pubmed/27847617 http://dx.doi.org/10.1186/s40942-015-0024-5 |
| _version_ | 1782464100722278400 |
|---|---|
| author | Reichel, Elias |
| author_facet | Reichel, Elias |
| author_sort | Reichel, Elias |
| collection | PubMed |
| description | The following is a response to Brown and colleagues (Int J Retin Vitr 1:19, 2015), who analyzed the cost effectiveness of genetic screening for neovascular AMD in Category 3 (intermediate). As explained in this letter, it is premature to propose that genetic screening is cost effective in this setting. A simple clinical history and macular exam is highly cost effective and can easily guide screening strategies. |
| format | Online Article Text |
| id | pubmed-5088460 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-50884602016-11-15 Genetic screening for neovascular AMD: cost effective…not so quick Reichel, Elias Int J Retina Vitreous Letter to the Editor The following is a response to Brown and colleagues (Int J Retin Vitr 1:19, 2015), who analyzed the cost effectiveness of genetic screening for neovascular AMD in Category 3 (intermediate). As explained in this letter, it is premature to propose that genetic screening is cost effective in this setting. A simple clinical history and macular exam is highly cost effective and can easily guide screening strategies. BioMed Central 2015-12-15 /pmc/articles/PMC5088460/ /pubmed/27847617 http://dx.doi.org/10.1186/s40942-015-0024-5 Text en © Reichel. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Letter to the Editor Reichel, Elias Genetic screening for neovascular AMD: cost effective…not so quick |
| title | Genetic screening for neovascular AMD: cost effective…not so quick |
| title_full | Genetic screening for neovascular AMD: cost effective…not so quick |
| title_fullStr | Genetic screening for neovascular AMD: cost effective…not so quick |
| title_full_unstemmed | Genetic screening for neovascular AMD: cost effective…not so quick |
| title_short | Genetic screening for neovascular AMD: cost effective…not so quick |
| title_sort | genetic screening for neovascular amd: cost effective…not so quick |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088460/ https://www.ncbi.nlm.nih.gov/pubmed/27847617 http://dx.doi.org/10.1186/s40942-015-0024-5 |
| work_keys_str_mv | AT reichelelias geneticscreeningforneovascularamdcosteffectivenotsoquick |